|
RFX7 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.58309999553907E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.1588999999933E-06 |
| Normal-vs-Stage2 |
2.232600E-04 |
| Normal-vs-Stage3 |
7.60460000526209E-08 |
| Normal-vs-Stage4 |
5.12129999519217E-08 |
| Stage1-vs-Stage2 |
6.877000E-01 |
| Stage1-vs-Stage3 |
1.358410E-01 |
| Stage1-vs-Stage4 |
1.904080E-02 |
| Stage2-vs-Stage3 |
5.112200E-01 |
| Stage2-vs-Stage4 |
1.143170E-01 |
| Stage3-vs-Stage4 |
2.205600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.29589999526326E-08 |
| Normal-vs-AfricanAmerican |
1.941600E-02 |
| Normal-vs-Asian |
2.26359999999648E-05 |
| Caucasian-vs-AfricanAmerican |
3.378000E-01 |
| Caucasian-vs-Asian |
6.399000E-01 |
| AfricanAmerican-vs-Asian |
2.252800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.9997000000902E-07 |
| Normal-vs-Female |
6.23289999612808E-08 |
| Male-vs-Female |
8.552600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.44209999994616E-06 |
| Normal-vs-Age(41-60Yrs) |
4.0738999995682E-07 |
| Normal-vs-Age(61-80Yrs) |
1.81969999957232E-07 |
| Normal-vs-Age(81-100Yrs) |
7.095700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.983600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.589830E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.408800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.362800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.748800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.641800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.684200E-02 |
| Classical-VS-Follicular |
1.731390E-01 |
| Classical-VS-Other |
2.558600E-01 |
| Classical-VS-Normal |
6.50109999944526E-07 |
| Tall-VS-Follicular |
6.029400E-01 |
| Tall-VS-Other |
8.020400E-01 |
| Tall-VS-Normal |
3.69260000000482E-05 |
| Follicular-VS-Other |
6.305800E-01 |
| Follicular-VS-Normal |
1.66684999999278E-05 |
| Other-VS-Normal |
9.655100E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.01869999991067E-07 |
| Normal-vs-N1 |
7.11310000012233E-07 |
| N0-vs-N1 |
2.921600E-01 |
|
|
